NVIDIA and Eli Lilly announced a $1 billion partnership to build an AI-powered drug discovery laboratory aimed at accelerating biologics and small‑molecule discovery. The collaboration will pair NVIDIA’s computing and AI infrastructure with Lilly’s drug‑development expertise to deploy platform models across multiple therapeutic programs. The lab is positioned as an industrial-scale effort to move AI from research pilots into routine discovery workflows. Companies plan to train and deploy models for molecule design, target prediction and translational analytics, signaling deeper tech‑pharma integration for preclinical R&D.